matching the right drug to the right patient based on underlying biology
A global consortium of 118 researchers has completed the largest genetic study of blood proteins ever undertaken, drawing on data from more than 78,000 participants across 38 cohorts to map the path from genetic variation to disease mechanism to therapeutic action. Published in Cell in May 2026, the work addresses one of medicine's most persistent frustrations: the gap between identifying disease-linked genes and translating that knowledge into treatments that actually reach patients. By tracing how genetic differences shape the proteins circulating in our blood, the study opens new routes to drug discovery and reveals opportunities to repurpose existing medicines — among them, evidence that TYK2 inhibitors approved for psoriasis may also benefit patients with rheumatoid arthritis. It is a reminder that the body's molecular language, once read carefully enough, may already contain many of the answers medicine has been searching for.
- Decades of large-scale genetic research have identified thousands of disease-linked genes, yet the clinical payoff has remained frustratingly out of reach — this study was built to close that gap.
- By analyzing blood proteins across 78,000 participants worldwide, researchers created a map connecting genetic variation to biological mechanism at a scale that smaller studies simply could not achieve.
- A striking early finding — that TYK2 inhibitors already approved for psoriasis may be repurposable for rheumatoid arthritis — illustrates how this approach can surface actionable insights hiding in existing data.
- Machine learning layered onto genetic analysis is deepening the team's ability to model how human biology actually works, moving precision medicine from aspiration toward practical clinical decision-making.
- The study is now pointing toward a future in which the right drug is matched to the right patient not by trial and error, but by reading the molecular signatures written into their blood.
A consortium of 118 researchers across 89 institutions has published what is now the largest genetic study of blood proteins ever conducted, analyzing data from more than 78,000 participants enrolled in 38 research cohorts worldwide. The work, appearing in Cell in May 2026, was designed to address a long-standing problem in medicine: scientists have grown skilled at identifying genes associated with disease, but translating those discoveries into treatments has proven far harder than anticipated.
Blood proteins offered the research team a powerful lens. Circulating proteins reflect the body's ongoing biological activity — they are markers of disease, indicators of metabolic state, and direct targets for drugs. By mapping how genetic variation shapes the production and regulation of these proteins, and connecting that map to known disease mechanisms, the team identified new pathways for both drug development and drug repurposing. One concrete finding: TYK2 inhibitors, already approved for psoriasis, show promise for treating rheumatoid arthritis — a discovery that exemplifies the precision medicine ideal of matching therapies to patients based on underlying biology.
Lead author Dr. Mine Koprulu of Queen Mary University of London noted that the ability to measure biological data at nearly every level of human biology has created an unprecedented opportunity to build a molecular understanding of disease. Professor Claudia Langenberg, who directed the study, credited the scale of global collaboration and the generosity of participants whose samples made the work possible. Professor Maik Pietzner highlighted the integration of machine learning with genetic analysis as a key methodological advance — one that not only deepens biological understanding but generates evidence to guide clinicians toward the most effective treatments for individual patients.
What distinguishes this study is its insistence on tracing the full chain: from genetic variation, through protein regulation, to disease mechanism, to drug action. That integrated path, now made navigable by the scale of available data and the sophistication of modern analytical tools, suggests that many of the answers precision medicine has long sought may already be encoded in the biology we are only now learning to read.
A consortium of 118 researchers working across 89 institutions has completed the largest genetic study of blood proteins ever attempted, analyzing data from more than 78,000 people enrolled in 38 different research cohorts around the world. The work, published in Cell on May 6, 2026, represents a significant shift in how scientists approach the translation of genetic discovery into actual medical treatment.
Proteins are the machinery of human biology. They build tissue, regulate metabolism, fight infection, and perform thousands of other functions that keep us alive. Our genes exist primarily to encode instructions for making proteins. Yet despite decades of large-scale genetic studies involving hundreds of thousands of participants, scientists have struggled to move from identifying disease-linked genes to understanding the specific proteins and biological mechanisms that actually cause illness. This gap between genetic discovery and clinical application has long frustrated the field.
Blood offers a unique window into human health. The proteins circulating in our bloodstream reflect what is happening throughout the body—they are markers of disease, indicators of metabolic state, and targets for intervention. By mapping how genetic variation influences the production and regulation of blood proteins, and then connecting that map to what is already known about genetic causes of disease, the research team identified new pathways to drug development and drug repurposing.
One concrete example illustrates the potential. The study found evidence suggesting that TYK2 inhibitors—drugs already approved and in use for psoriasis—could be repurposed to treat rheumatoid arthritis. This kind of insight, drawn from the integration of genetic data with clinical knowledge, represents the kind of precision medicine the field has long pursued: matching the right drug to the right patient based on underlying biology rather than trial and error.
Dr. Mine Koprulu, a senior postdoctoral researcher at Queen Mary University of London's Precision Healthcare University Research Institute and a lead author, emphasized the moment the field has reached. Measurements of biological data are now possible at nearly every level of human biology, she noted, creating an opportunity to develop a molecular understanding of diverse diseases and to accelerate the discovery of new drug targets or candidates for repurposing.
Professor Claudia Langenberg, who directed the study and leads the Precision Healthcare University Research Institute at Queen Mary, stressed that the work depended on the collaboration of scientists worldwide and on the generosity of study participants who contributed their time and biological samples. The scale and integration of data across so many cohorts made insights possible that would have been invisible in smaller studies.
Professor Maik Pietzner, a senior co-lead and professor of health data modeling at the Berlin Institute of Health, highlighted two particular achievements. The first was the use of machine learning alongside genetic analysis to deepen understanding of how human biology actually works. The second was the generation of evidence that could help clinicians and researchers identify which drugs would work best for which patients—a fundamental goal of precision medicine that has remained elusive.
The study signals a shift in how genetic research translates into clinical benefit. Rather than stopping at the identification of disease-associated genes, the work traces the path from genetic variation through protein regulation to disease mechanism to drug action. This integrated approach, enabled by the scale of data and the sophistication of analytical tools now available, opens new avenues for both discovering entirely new treatments and finding new uses for drugs already in the clinic.
Citações Notáveis
We are at a point where scalable measurements are possible at almost all layers of biology, giving us an opportunity to gain a molecular view into diverse diseases and accelerate discovery of new drug targets.— Dr. Mine Koprulu, Senior Postdoctoral Researcher, Queen Mary University of London
Our study demonstrates how human molecular data can deliver new opportunities for precision medicine when generated at scale and integrated with clinical knowledge.— Professor Claudia Langenberg, Director of the Precision Healthcare University Research Institute
A Conversa do Hearth Outra perspectiva sobre a história
What makes this study different from the genetic research that came before it?
Scale matters, but it's not just about numbers. Previous studies found genes linked to disease, but they often couldn't explain why those genes mattered or what proteins they affected. This study connects the dots—it shows how genetic variation changes protein levels in blood, and then links that to actual disease mechanisms.
So it's the integration that's novel?
Exactly. You have genetic data, protein data, clinical knowledge, and machine learning all working together. That combination reveals things none of them could show alone.
The TYK2 inhibitor example—how does that actually help a patient with rheumatoid arthritis?
Instead of waiting years for a new drug to be developed and tested, doctors might be able to use a drug already approved for another condition. The study provides evidence that it could work. That compresses the timeline from discovery to treatment.
Does this mean we're finally closing the gap between genetic discovery and clinical benefit?
We're making real progress. The gap hasn't closed entirely, but for the first time, we have tools and data at scale that let us trace the path from gene to protein to disease to drug. That's the precision medicine promise actually starting to materialize.
What happens next with this data?
Other researchers will use it to identify new drug targets, to understand disease mechanisms better, and to test whether other approved drugs might work for conditions they weren't originally designed for. The dataset becomes a resource for the entire field.